Event: ESH MDS 2021

0:04:05

The 2021 MDS armamentarium

0:02:29

The 7th ESH Translational Research E-Conference on MDS

0:01:27

Key clinical trials in high-risk and low-risk MDS

0:01:25

Novel strategies for treating cytopenia in MDS

0:02:18

Prognostic factors and mutations in MDS

0:01:23

Immunological impact of TP53 in MDS

0:07:18

Immune dysregulation and drug selection in MDS

0:02:43

Novel therapies in the future of MDS treatment

0:05:05

Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246

0:02:30

MEDALIST: luspatercept and erythropoiesis biomarkers in MDS

0:04:17

MDS clinical trials: the European effort

0:04:26

Promising therapies on the horizon for MDS

0:02:58

Impact of environmental factors on MDS

0:05:17

ESA and other growth factors for MDS

0:05:36

MDS biology: somatic mutations, the microenvironment & inflammation

0:03:06

MDS highlights at ASH: Refined prognostication tools and novel combination therapies

0:02:42

Dose modification strategies in high-risk MDS treated with venetoclax and azacitidine

0:02:32

Reduced-intensity conditioning regimens for adults with ALL: UKALL14 & ALL-RIC

0:04:35

Lower-risk MDS in 2021: luspatercept, imetelstat & roxadustat

0:03:03

Etiology and genetic profile of t-MDS

0:02:19

Phase I trial of CA-4948 in AML or MDS

0:02:23

Evolution of multiple myeloma treatment in Norway

0:03:32

MDS: managing HMA failure

0:02:00

Imetelstat in heavily-transfused lower-risk R/R MDS